Sangamo Therapeutics (SGMO) NASDAQ US 18 Mar 2026: Market closed, earnings tonight

SGMO stock closed at $0.36 on NASDAQ in the United States on 18 Mar 2026 as investors wait for tonight’s Q4 earnings announcement at 16:00 EDT (20:00 UTC). We see heightened volume at 8,305,912.00 shares and a day range of $0.36–$0.39, reflecting short-term pressure after a -5.26% intraday move. Sangamo Therapeutics, Inc. (SGMO) reports amid a thin cash runway, negative EPS of -0.45, and clinical readouts that could swing sentiment. This earnings spotlight highlights guidance, cash use, and clinical milestones that will drive SGMO stock in the next 24–72 hours

SGMO stock: Earnings preview and what to expect

Sangamo Therapeutics (SGMO) reports Q4 results tonight, and we expect commentary on cash, R&D pacing, and the Phase III hemophilia A program. Analysts note a trailing EPS of -0.44, and consensus currently leans buy (4 buys, 0 holds), but the market will react to near-term funding and guidance. Watch management remarks on trial timelines and partnership milestones, which are the likeliest catalysts for SGMO stock in this release

Q4 financials and analyst focus for SGMO earnings

Key numbers to watch are revenue versus R&D spend, operating cash flow, and updated cash runway. On a trailing basis Sangamo shows EPS -0.45, PE -0.82, market cap $136,631,325.00, and shares outstanding 371,684,781.00. Analysts will read any shift in operating cash flow per share (currently -0.25) as a signal for near-term financing risks that can move SGMO stock materially

Pipeline milestones that could move SGMO stock

Clinical program updates are central: Phase III AFFINE (SB-525) for hemophilia A, ST-920 for Fabry disease, and cell therapies in sickle cell programs. Positive safety or efficacy news could lift sentiment quickly; delays or added enrollment needs would likely pressure SGMO stock. Partnerships with Big Pharma are an ongoing upside; investors should track any advancement or collaboration terms announced alongside results

Valuation, liquidity and risks in SGMO analysis

Sangamo trades below its 50-day average ($0.41) and 200-day average ($0.50), with price-to-sales 4.18 and PB around 18.01, reflecting deep negative earnings and low book value per share. Current ratio is 0.88, debt-to-equity 4.07, and cash per share 0.10, all pointing to liquidity risk if clinical spend rises. These fundamentals are commonly cited in SGMO analysis as key downside drivers

Technical and trading snapshot for SGMO stock

Short-term momentum is weak: RSI 43.68, MACD roughly neutral, and average volume higher at 5,842,518.00 shares versus this session’s 8,305,912.00. Bollinger Bands run $0.34–$0.46, indicating room for volatility. Traders should watch intraday volume and option flow for swift moves in SGMO stock after earnings

Meyka AI rates SGMO with a score out of 100 and forecast

Meyka AI rates SGMO with a score out of 100: 69.52 (Grade B, Suggestion: HOLD). This grade factors in S&P 500 and sector comparison, financial growth, key metrics, analyst consensus, and forecasts. Meyka AI’s forecast model projects a monthly value of $0.08, which implies -77.78% versus the current price $0.36; forecasts are model-based projections and not guarantees. We flag that the stock shows analyst consensus skewed to buys but material execution and funding risk remain

Final Thoughts

Earnings tonight are a near-term catalyst for SGMO stock and should clarify cash needs and trial timelines. At $0.36, Sangamo carries high volatility and clinical binary risk, with a market cap of $136,631,325.00 and negative EPS -0.45. Our technical read suggests limited upside without clear guidance on financing or positive clinical news. Meyka AI’s forecast model projects $0.08, implying -77.78% from the current price, which highlights downside risk under our base-case model. For investors we outline three scenarios: a conservative 12-month target $0.25, base case $0.50, and bullish clinical-outcome target $1.00. These targets reflect the stock’s low liquidity, high R&D spend, and binary pipeline events. Use tonight’s report to reassess cash runway and whether clinical milestones justify holding SGMO stock; Meyka AI provides this as AI-powered market analysis, not investment advice

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.